New Delhi: A study has revealed that Covishield vaccine is better than Covaxin in terms of dealing with different variants of corona. Covishield has emerged as a more effective vaccine in studies conducted in several places. Covishield has proved to be more effective against the SARS-CoV-2 virus and its other variants in terms of making antibodies (a virus neutralising protein). It is worth mentioning that Covaxin was developed in India.
This study is yet to be reviewed by other experts. According to the study, when compared with the level before taking the vaccine, it was revealed that both the vaccines helped to produce enough antibodies. But the antibodies made by Covishield were more effective and longer lasting than the antibodies made by Covaxin. Between June 2021 and January 2022, scientists conducted the experiment on 691 people aged 18-45 years. All of them belonged to four urban and rural areas of Bengaluru and Pune.
Participants in this study had taken both doses of Covaxin and Covishield within the stipulated time. At two of these places, the wave of the Omicron variant of corona came in early 2022 when the second dose of the vaccine was received, and at one place when the person had taken both doses. Samples of participants in the study were taken for antibody analysis at six different times.
Samples were taken four times for cellular analysis. Vinita Bal, a scientist at IISER-Pune, said the impact of Covid vaccines has been different in the young adult population.